National Institute for Health and Care Excellence says ‘yes’ to Darzalex®▼ (daratumumab) for relapsed and refractory multiple myeloma High Wycombe, 15th March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson welcomes the decision by the National Institute for Health and.
National Institute for Health and Care Excellence Backs Darzalex®▼ (daratumumab) in Combination with Velcade® (bortezomib), Thalidomide and Dexamethasone (DVTd) for Patients with Newly Diagnosed Multiple Myeloma High Wycombe, 22nd December 2021 – The Janssen Pharmaceutical Companies of Johnson &a.
NICE Recommends VENCLYXTO®▼(Venetoclax) Combination in Certain Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia (AML) ­ Venetoclax in combination with azacitidine will be immediately available tountreated adult patients with AML unable to recei.
Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive. - News - PharmaTimes